189 related articles for article (PubMed ID: 6437365)
21. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
[TBL] [Abstract][Full Text] [Related]
22. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
23. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
Hogarty GE; Schooler NR; Ulrich R; Mussare F; Ferro P; Herron E
Arch Gen Psychiatry; 1979 Nov; 36(12):1283-94. PubMed ID: 227340
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
[TBL] [Abstract][Full Text] [Related]
25. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
Altamura AC; Mauri MC; Guercetti G; Cazzullo CL
Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):613-23. PubMed ID: 3122268
[TBL] [Abstract][Full Text] [Related]
26. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Landmark J; Merskey H; Cernovsky ZZ
Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
[TBL] [Abstract][Full Text] [Related]
27. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
[TBL] [Abstract][Full Text] [Related]
28. Institutional management of chronic schizophrenics with fluphenazine decanoate.
Neal CD; Imlah NW
Dis Nerv Syst; 1970 Sep; 31():Suppl:24-7. PubMed ID: 4920310
[No Abstract] [Full Text] [Related]
29. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
30. Fluphenazine decanoate: a clinical problem?
Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
[TBL] [Abstract][Full Text] [Related]
31. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
32. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
[TBL] [Abstract][Full Text] [Related]
33. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
34. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
[TBL] [Abstract][Full Text] [Related]
35. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
Russell N; Landmark J; Merskey H; Turpin T
Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
[TBL] [Abstract][Full Text] [Related]
36. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG
Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099
[TBL] [Abstract][Full Text] [Related]
37. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
38. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
39. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
Schooler NR; Levine J; Severe JB; Brauzer B; DiMascio A; Klerman GL; Tuason VB
Arch Gen Psychiatry; 1980 Jan; 37(1):16-24. PubMed ID: 7352836
[TBL] [Abstract][Full Text] [Related]
40. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
